Expansion Opportunity GAVIS plans 8-10 new product launches in the next 12 months, presenting a strong opportunity to position sales outreach around distribution partnerships, exclusive SKUs, and rapid onboarding with major wholesalers and group purchasing organizations.

Auth/ABLA Pipeline With 24 ANDAs filed and awaiting FDA approval, there is a near-term potential to align sales efforts with product approvals, securing distribution and co-promotion opportunities as these products enter the US market.

In-House Fulfillment Operating its own 42,000 sq ft facility and shipping without a 3PL suggests reliability and control over supply, enabling sales pitches focused on faster replenishment cycles and consistent product availability to key distributors and chain pharmacies.

Strategic Market Fit As a niche drug product distributor with existing relationships to major wholesalers, distributors, and group purchasing organizations, there is potential to expand footprint by targeting mid-market accounts and regional chains seeking differentiated specialty products.

Competitive Positioning Smaller headcount but direct import and distribution capabilities can be framed as a cost-efficient, agile partner for customers looking to diversify suppliers, reduce dependency on larger players, and access a broader portfolio through a nimble supplier.